Literature DB >> 24629797

Immunotherapy: opportunities, risks and future perspectives.

Martin Hildebrandt1, Karl Peggs2, Lutz Uharek3, Catherine M Bollard4, Helen E Heslop5.   

Abstract

This review is intended to reflect upon the current status and perspectives of cell-based immunotherapy at a time when the promise of extensive pre-clinical research has been translated into encouraging clinical responses. However, some of these have also been complicated by significant adverse reactions. As the field moves towards definitive late stage trials, with a growing interest from pharmaceutical companies, we realize that novel cell therapy strategies pose questions that are familiar to traditional drug development, along with new considerations due to the potential of T cells to persist long term and to expand after adoptive transfer. These questions address the safety of the product, the efficacy, the mode of action, and the anticipation of risks. From different perspectives, we intend to address exciting opportunities and safety concerns in current concepts of cellular immunotherapy.
Copyright © 2014 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  T cell receptor; clinical trials; gene therapy; immunotherapy; safety; treatment efficacy

Mesh:

Substances:

Year:  2014        PMID: 24629797      PMCID: PMC4108615          DOI: 10.1016/j.jcyt.2014.02.001

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  67 in total

1.  T cell activation upon exposure to patient-derived tumor tissue: a functional assay to select patients for adoptive T cell therapy.

Authors:  Caroline Schroten; Robert Kraaij; Joke L M Veldhoven; Cor A Berrevoets; Michael A den Bakker; Qiangzhong Ma; Michel Sadelain; Chris H Bangma; Ralph A Willemsen; Reno Debets
Journal:  J Immunol Methods       Date:  2010-05-09       Impact factor: 2.303

2.  Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.

Authors:  Conrad R Cruz; Ulrike Gerdemann; Ann M Leen; Jessica A Shafer; Stephanie Ku; Benjamin Tzou; Terzah M Horton; Andrea Sheehan; Amanda Copeland; Anas Younes; Cliona M Rooney; Helen E Heslop; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2011-09-09       Impact factor: 12.531

3.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

Authors:  Renier J Brentjens; Isabelle Rivière; Jae H Park; Marco L Davila; Xiuyan Wang; Jolanta Stefanski; Clare Taylor; Raymond Yeh; Shirley Bartido; Oriana Borquez-Ojeda; Malgorzata Olszewska; Yvette Bernal; Hollie Pegram; Mark Przybylowski; Daniel Hollyman; Yelena Usachenko; Domenick Pirraglia; James Hosey; Elmer Santos; Elizabeth Halton; Peter Maslak; David Scheinberg; Joseph Jurcic; Mark Heaney; Glenn Heller; Mark Frattini; Michel Sadelain
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

4.  Resistance of mature T cells to oncogene transformation.

Authors:  Sebastian Newrzela; Kerstin Cornils; Zhixiong Li; Christopher Baum; Martijn H Brugman; Marianne Hartmann; Johann Meyer; Sylvia Hartmann; Martin-Leo Hansmann; Boris Fehse; Dorothee von Laer
Journal:  Blood       Date:  2008-06-19       Impact factor: 22.113

5.  Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.

Authors:  Patrick J Hanley; Conrad Russell Young Cruz; Barbara Savoldo; Ann M Leen; Maja Stanojevic; Mariam Khalil; William Decker; Jeffrey J Molldrem; Hao Liu; Adrian P Gee; Cliona M Rooney; Helen E Heslop; Gianpietro Dotti; Malcolm K Brenner; Elizabeth J Shpall; Catherine M Bollard
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

6.  Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant.

Authors:  G Weber; U Gerdemann; I Caruana; B Savoldo; N F Hensel; K R Rabin; E J Shpall; J J Melenhorst; A M Leen; A J Barrett; C M Bollard
Journal:  Leukemia       Date:  2013-03-01       Impact factor: 11.528

7.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

8.  Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation.

Authors:  Karl S Peggs; Stephanie Verfuerth; Arnold Pizzey; Shoon-Ling C Chow; Kirsty Thomson; Stephen Mackinnon
Journal:  Clin Infect Dis       Date:  2009-12-15       Impact factor: 9.079

9.  Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes.

Authors:  H E Heslop; C Y Ng; C Li; C A Smith; S K Loftin; R A Krance; M K Brenner; C M Rooney
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

10.  A human memory T cell subset with stem cell-like properties.

Authors:  Luca Gattinoni; Enrico Lugli; Yun Ji; Zoltan Pos; Chrystal M Paulos; Máire F Quigley; Jorge R Almeida; Emma Gostick; Zhiya Yu; Carmine Carpenito; Ena Wang; Daniel C Douek; David A Price; Carl H June; Francesco M Marincola; Mario Roederer; Nicholas P Restifo
Journal:  Nat Med       Date:  2011-09-18       Impact factor: 53.440

View more
  4 in total

Review 1.  HIV-specific CD8⁺ T cells and HIV eradication.

Authors:  R Brad Jones; Bruce D Walker
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

Review 2.  Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors.

Authors:  Hiroshi Fujiwara
Journal:  Pharmaceuticals (Basel)       Date:  2014-12-15

3.  Effect of Doxorubicin on the Near-Infrared Optical Properties of Indocyanine Green.

Authors:  Saumya Jaiswal; Surjendu Bikash Dutta; Debasis Nayak; Sharad Gupta
Journal:  ACS Omega       Date:  2021-12-10

4.  Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies.

Authors:  Hao Huang; Ling Peng; Bicheng Zhang; Brian G Till; Yonghao Yang; Xiaojie Zhang; Lingdi Zhao; Xiaomin Fu; Tiepeng Li; Lu Han; Peng Qin; Lin Chen; Xiang Yan; Yang Liu; Wenkang Wang; Zhenlong Ye; Hongle Li; Quanli Gao; Zibing Wang
Journal:  Front Immunol       Date:  2022-07-13       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.